Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in EGFR/ALK+ NSCLC
NCT03256136Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03256136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256136.